Anavex Life Sciences
AVXL
147 hedge funds and large institutions have $252M invested in Anavex Life Sciences in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 51 increasing their positions, 32 reducing their positions, and 19 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 32
1% more capital invested
Capital invested by funds: $249M → $252M (+$2.15M)
0.9% less ownership
Funds ownership: 32.18% → 31.28% (-0.9%)
2% less funds holding
Funds holding: 150 → 147 (-3)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
33% less call options, than puts
Call options by funds: $15.2M | Put options by funds: $22.7M
Top Buyers
| 1 |
Barclays
London,
United Kingdom
|
+$1.89M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.46M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
| 4 |
Rafferty Asset Management
New York
|
+$1.13M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$971K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$6.61M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$4.24M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.45M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.35M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$1.33M |
AVXL Hedge Fund Activity: Q3 2022 in Review
147 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q3 2022, worth a combined $252M — up 0.86% from $249M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AVXL and 16 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 51 added.
The largest buyer was Barclays, adding an estimated $1.89M. The largest seller was Morgan Stanley, cutting an estimated $6.61M.
- 147 institutional investors held Anavex Life Sciences (AVXL) as of Q3 2022, down from 150 in Q2 2022.
- Funds reported $252M of Anavex Life Sciences stock for Q3 2022, up 0.86% quarter-over-quarter.
- 16 funds opened new Anavex Life Sciences positions in Q3 2022 and 19 closed out, a net change of -3 holders.
- The largest Anavex Life Sciences buyer in Q3 2022 was Barclays, an estimated $1.89M added.
- The largest Anavex Life Sciences seller in Q3 2022 was Morgan Stanley, an estimated $6.61M sold.
Based on aggregated 13F filings for Q3 2022.